Clinical Trial Detail

NCT ID NCT02641093
Title Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Trisha Wise-Draper
Indications

head and neck squamous cell carcinoma

Therapies

Cisplatin

Pembrolizumab

Age Groups: adult

No variant requirements are available.